Epitarget: Bombarding Tumors with Sound

Liposomes are attractive delivery agents for chemotherapeutics because they preferentially accumulate in tumors, thereby minimizing the effects of their drug payload on healthy tissue. But existing liposome technologies release only a fraction of that payload inside the tumor, limiting the effectiveness of the therapy.

Epitarget A/S has gotten around this problem by developing ultrasound-activated liposomes. The company has data from in vitro studies showing its liposomes release more doxorubicin than Caelyx (Doxil - U.S.), a marketed liposomal doxorubicin from Johnson & Johnson and Schering-Plough Corp...